202 related articles for article (PubMed ID: 25952785)
1. Molecular pathogenesis of ovarian clear cell carcinoma.
Gounaris I; Brenton JD
Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
[TBL] [Abstract][Full Text] [Related]
2. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
3. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
Lowery WJ; Schildkraut JM; Akushevich L; Bentley R; Marks JR; Huntsman D; Berchuck A
Int J Gynecol Cancer; 2012 Jan; 22(1):9-14. PubMed ID: 22193641
[TBL] [Abstract][Full Text] [Related]
5. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
6. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
7. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
8. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
Matsumoto T; Yamazaki M; Takahashi H; Kajita S; Suzuki E; Tsuruta T; Saegusa M
Am J Clin Pathol; 2015 Sep; 144(3):452-63. PubMed ID: 26276776
[TBL] [Abstract][Full Text] [Related]
9. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
11. Endometriosis-associated Ovarian Cancers.
Anglesio MS; Yong PJ
Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
[TBL] [Abstract][Full Text] [Related]
12. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
13. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
15. [Advances in origin and pathogenesis of epithelial ovarian cancer].
Liu CR; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):569-72. PubMed ID: 22169654
[No Abstract] [Full Text] [Related]
16. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
Matsuo Y; Tashiro H; Yanai H; Moriya T; Katabuchi H
Med Mol Morphol; 2015 Sep; 48(3):146-54. PubMed ID: 25398420
[TBL] [Abstract][Full Text] [Related]
18. ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis.
Yachida N; Yoshihara K; Suda K; Nakaoka H; Ueda H; Sugino K; Yamaguchi M; Mori Y; Yamawaki K; Tamura R; Ishiguro T; Isobe M; Motoyama T; Inoue I; Enomoto T
Sci Rep; 2020 Aug; 10(1):14260. PubMed ID: 32868822
[TBL] [Abstract][Full Text] [Related]
19. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
20.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
